Outlook Therapeutics Inc News - OTLKW

Current Report Filing (8-k)

0001649989 false 0001649989 2021-12-21 2021-12-21 0001649989 us-gaap:CommonStockMember 2021-12-21 2021-12-21 0001649989 otlk:SeriesAW...

Annual Report (10-k)

P1YP1Y0001649989--09-302021FYfalseP8MP4YP2Y00000000176461628127183109P1YP5Y0.350.670.350.671526761457255...

Current Report Filing (8-k)

0001649989 false 0001649989 2021-12-22 2021-12-22 0001649989 us-gaap:CommonStockMember 2021-12-22 2021-12-22 0001649989 otlk:SeriesAW...

Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update

Positive clinical data reported for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) in 2021 from multiple clinical...

Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

ISELIN, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress

ISELIN, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE...

Current Report Filing (8-k)

0001649989 false 0001649989 2021-11-23 2021-11-23 0001649989 us-gaap:CommonStockMember 2021-11-23 2021-11-23 0001649989 otlk:SeriesAW...

Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

ISELIN, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Outlook Therapeutics Inc (OTLKW)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

OTLKW News

Current Report Filing (8-k)

Annual Report (10-k)

Current Report Filing (8-k)

Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update

Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Beneficial Ownership (sc 13d/a)

Current Report Filing (8-k)

Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million

Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

OTLKW Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Outlook Therapeutics Inc (OTLKW) News

Outlook Therapeutics Inc (OTLKW)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

OTLKW News

Current Report Filing (8-k)

Annual Report (10-k)

Current Report Filing (8-k)

Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update

Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Beneficial Ownership (sc 13d/a)

Current Report Filing (8-k)

Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million

Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

OTLKW Discussion

Your Recent History